DOCSLIB.ORG

Global Smart Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Smart Update March 11 VOLUME GLOBAL SMART UPDATE GLOBAL SMART UPDATE Special Segment The changing nature of “ecstasy”20132014 About the SMART Update The threat of synthetic drugs is one of the most sig- The Update reports various synthetic drug informa- nificant drug problems worldwide. After cannabis, tion, such as significant or unusual drug or precursor amphetamine-type stimulants (ATS) are the second seizures, new locations, methods and chemicals used most widely used drugs across the globe, outstrip- for clandestine manufacture, new trafficking groups ping the use of cocaine and heroin. Since 1990 the or routes, changes in legislation to address the illicit manufacture of ATS has been reported problem of synthetic drugs, emerging drugs or from more than 70 countries and the figure user groups, and health implications related keeps rising. Along with ATS, the continued to their use.* growth of the new psychoactive substances (NPS) market over previous years has be- come a policy challenge and a major interna- tional concern. A growing interplay between In this issue the new drugs and illicit drug markets is being observed. By October 2013, the emergence of NPS Each issue of the Update contains a special coverage had been reported in more than 85 countries and ter- and thematic segments. Previous issues highlighted ritories. Trends on the synthetic drug market evolve the increasing dimension of ATS trafficking from -Af quickly each year. rica to East and South-East Asia; the ATS situation in South Asia; the changing faces of illicit ATS manu- The UNODC Global Synthetics Monitoring: Analyses, facture; the spread of new psychoactive substances Reporting and Trends (SMART) Programme enhances across the globe and, the legal situation and respons- the capacity of Member States in priority regions to es to the challenge of new psychoactive substances generate, manage, analyse, report and use synthetic and the road ahead. drug information to design effective policy and pro- gramme interventions. Launched in Septem- The special segment of the current issue ad- ber 2008, Global SMART provides capacity dresses the changing nature of the content building in East and South-East Asia, the Pa- of drugs and substances sold as “ecstasy”. cific, Latin America and Africa and regularly For this purpose, the historical background reviews the global ATS situation. Features of of MDMA and the original active compo- UNODC Global SMART are online data col- nent of ecstasy is outlined; a description of lection, situation reports and regional assess- MDMA, its legal status and its mechanism of ments. The first global situation assessment on action is presented and reported adverse effects NPS “The challenge of new psychoactive substances” associated with its use are briefly summarized. Final- was published in March 2013, pursuant to Commis- ly, the composition of pills currently sold as “ecstasy” sion on Narcotic Drugs resolution 55/1 (2012). The is discussed. SMART Early Warning Advisory web-portal offers reg- ularly updated information on NPS and related legis- While data on ATS seizures is often easy to obtain, in- lation (https://www.unodc.org/NPS). formation on the demand for ATS and NPS remains scarce and anecdotal in nature. Nevertheless, the Up- The Global SMART Update is designed to provide regu- date continues to make a determined effort to high- lar brief reporting on emerging patterns and trends of light information on ATS and NPS use. Various drug the global synthetic drug situation. Given the speed at demand-related subjects are covered in this issue, which changes in the ATS and NPS markets occur, including facts that have come to light on the it is especially important to have a simple sus- combined use of MDMA and new psychoac- tainable mechanism for frequent information tive substances and their impact in selected sharing from different parts of the world. countries. The Update also covers the latest The Global SMART Update is published twice developments in the illicit manufacture of a year and is available in English and Spanish. ecstasy in Europe and the increasing use of Electronic copies of the SMART Updates and ecstasy in a powdered form, which is report- other publications are available at http://www. ed to be rapidly gaining prominence in some unodc.org/unodc/en/scientists/smart.html. regions of the world. *The information and data contained within this report are from official Government reports, press releases, scientific journals or incidents confirmed by UNODC Field Offices. Additional or updated information from previously reported incidents may also be included where appropriate. Information denoted with an asterisk (*) are from ‘open sources’ where UNODC is waiting for official confirmation and therefore should be considered only preliminary. This report has not been formally edited. The contents of this publication do not necessarily reflect the views or policies of UNODC or contributory organizations and neither do they imply any endorsement. Suggested citation: Global SMART Update Volume 11, March 2014. Cover picture © U.S. Customs and Border Protection. 2 The changing nature of “ecstasy”1 3,4-Methylenedioxymethamphetamine (MDMA) was For instance, of the two million past-year users of “ec- the original chemical found in pills sold as ecstasy and stasy” in Europe, 1.5 million were between 15 and 34 the two names have been used interchangeably.2 How- years of age.4 Oceania (2.9 per cent), North America ever, in the last few decades several substances under (0.9 per cent) and Europe (0.7 per cent) are the three international control and new psychoactive substances regions with the highest prevalence of ‘ecstasy’ use, ac- (NPS) that mimic or produce effects similar to MDMA, cording to the latest estimates.5 have been identified as components of pills sold as “ec- stasy”. Chemical analyses of “ecstasy” pills around the What is MDMA? world have revealed that their composition is rather MDMA is a derivative of amphetamine and a member diverse, varying from products with MDMA as the sole of the phenethylamine family. MDMA and its chemical psychoactive substance, through mixtures of MDMA analogues such as 3,4-methylenedioxyamphetamine with other psychoactive substances, to pills which (MDA)6 and 3,4-methylenedioxyethylamphetamine do not contain MDMA but rather other psychoactive (MDEA)7 belong to the more general category com- substances which mimic its effects. Thus, users can no monly referred to as ecstasy-group substances. longer be certain of the content of pills sold as “ecsta- sy” and are thereby exposed to increased health risks MDMA hydrochloride, a white or off-white powder or and potentially dangerous effects. In addition, data on crystals, is the most common salt form and is soluble in prevalence of MDMA use may be inaccurate due to the water. MDMA is usually made into brightly coloured varying composition of “ecstasy”. pills or capsules and sold as ecstasy for oral use. It is also available in a powder form for nasal insufflation MDMA, a failed medicine (snorting). Ecstasy can also be prepared for injection, The German pharmaceutical company, Merck, first filed although this mode of administration is uncommon. a patent for MDMA in 1912. Although the patent was Recent reports from Australia and the United States issued in 1914, it was not immediately investigated for have pointed to an increased presence of MDMA in use as a pharmaceutical product. In 1960, the synthesis powder as well as crystalline forms on the market. The of MDMA was reported for the first time followed by powder form of MDMA is associated with the street reports of its use in humans during the latter part of name “Molly”. Pills sold as “ecstasy” in the market are that decade. During the 1970s, MDMA was introduced known by names such as “E”; “X”; “XTC”; “Rolls”; in clinical psychotherapy in the United States, although “Beans”; “Adam”; “Molly” (powdered ecstasy), in addi- the drug had never undergone formal clinical trials and tion to other names that often reflect the imprinted was therefore not approved for use in humans. By the logo in the pills, e.g. “Mitsubishi”, “Playboy”, “Rolex”, late 1970s and early 1980s, MDMA gained popularity in and many others. psychiatric practice. In 1970, MDMA was detected for the first time in pills seized in the United States, but it was only during the late 1970s and early 1980s that MDMA became popu- Source: Ecstasydata.org lar among urban communities in the United States. By How is MDMA obtained? the mid-1980s, the use of ecstasy (the street name for MDMA coined in California partly due to feelings of The primary precursors of MDMA are safrole (includ- euphoria and emotional warmth caused by the drug) ing in the form of safrole rich oils (SRO)), isosafrole, pi- became popular in the nightclub and electronic music peronal and 3,4-methylenedioxyphenyl-2-propanone scenes, and spread to the European continent and Oce- (3,4-MDP-2-P, also known as PMK). SRO occurs natu- ania. In 1985, the United States placed MDMA under rally in over 360 tree species in South-East Asia. The temporary control and was brought under permanent oil is obtained from tree trunks, roots, bark, branches control under the Controlled Substances Act (Sched- and leaves, and is used legitimately in the fragrance ule I) in 1988, after being deemed to have no medical and insecticide industries. In Cambodia, SRO is extract- use, and a high potential for abuse. MDMA became an ed from the tree locally known as Mreas Prov Phnom, internationally controlled substance in 1986, and it is but the production, import, or export of SRO is prohib- currently listed in Schedule I of the 1971 Convention ited in the country, to prevent its use as a precursor on Psychotropic Substances3 together with its chemical for MDMA.
Load more

Recommended publications
  • International Collaborative Exercises (Ice)
    INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP) INTERNATIONAL COLLABORATIVE EXERCISES (ICE) Summary Report BIOLOGICAL SPECIMENS 2013/2 INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP) INTERNATIONAL COLLABORATIVE EXERCISES (ICE) Table of contents Introduction Page 3 Comments from the International Panel of Forensic Experts Page 3 Codes and Abbreviations Page 4 Sample 1 Analysis Page 5 Identified substances Page 5 Statement of findings Page 6 Identification methods Page 10 Summary Page 12 Z-Scores Page 13 Sample 2 Analysis Page 15 Identified substances Page 15 Statement of findings Page 16 Identification methods Page 20 Summary Page 22 Z-Scores Page 23 Sample 3 Analysis Page 25 Identified substances Page 25 Statement of findings Page 27 Identification methods Page 31 Summary Page 33 Z-Scores Page 34 Sample 4 Analysis Page 36 Identified substances Page 36 Statement of findings Page 38 Identification methods Page 42 Summary Page 44 Test Samples Information Samples Comments on samples Sample 1 To prepare BS-1, urine was spiked with 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) (1590 ng base/ml), as an ethanolic solution. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 2 To prepare BS-2, urine was spiked with Gammahydroxybutyrate (GHB) (14360 ng base/ml), as an aqueous solution. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 3 To prepare BS-3, urine was spiked with Amfetamine sulphate (1570ng/ml, 1150 ng base/ml) and Metamfetamine hydrochloride (4290 ng/ml, 3450 ng base/ml) as aqueous solutions. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 4 BS-4 was a blank test sample containing no substances in the ICE menu Samples Substances Concentrations Comments on substances Sample 1 4-Bromo-2,5-dimethoxyphenethylamine (2C- 1590 ng/ml B) Sample 2 gamma-Hydroxybutyric acid (GHB) 14360 ng/ml Sample 3 Metamfetamine 3450 ng/ml Amfetamine 1150 ng/ml Sample 4 [blank sample] This report contains the data received from laboratories participating in the current exercise.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • The Link Between Drugs and Music Explained by Science 25 January 2018, by Ian Hamilton, Harry Sumnall and Suzi Gage
    The link between drugs and music explained by science 25 January 2018, by Ian Hamilton, Harry Sumnall And Suzi Gage two key compounds in cannabis, tetrahydrocannabinol and cannabidiols, influence the desire for music and its pleasure. Cannabis users reported that they experienced greater pleasure from music when they used cannabis containing cannabidiols than when these compounds were absent. Listening to music – without the influence of drugs – is rewarding, can reduce stress (depending upon the type of music listened to) and improve feelings of belonging to a social group. But research Credit: Henny van Roomen/Shutterstock.com suggests that some drugs change the experience of listening to music. Clinical studies that have administered LSD to For centuries, musicians have used drugs to human volunteers have found that the drug enhance creativity and listeners have used drugs enhances music-evoked emotion, with volunteers to heighten the pleasure created by music. And the more likely to report feelings of wonder, two riff off each other, endlessly. The relationship transcendence, power and tenderness. Brain between drugs and music is also reflected in lyrics imaging studies also suggest that taking LSD while and in the way these lyrics were composed by listening to music, affects a part of the brain leading musicians, some of whom were undoubtedly to an increase in musically inspired complex visual influenced by the copious amounts of heroin, imagery. cocaine and "reefer" they consumed, as their songs sometimes reveal. Pairing music and drugs Acid rock would never have happened without Certain styles of music match the effects of certain LSD, and house music, with its repetitive 4/4 beats, drugs.
    [Show full text]
  • About Emotions There Are 8 Primary Emotions. You Are Born with These
    About Emotions There are 8 primary emotions. You are born with these emotions wired into your brain. That wiring causes your body to react in certain ways and for you to have certain urges when the emotion arises. Here is a list of primary emotions: Eight Primary Emotions Anger: fury, outrage, wrath, irritability, hostility, resentment and violence. Sadness: grief, sorrow, gloom, melancholy, despair, loneliness, and depression. Fear: anxiety, apprehension, nervousness, dread, fright, and panic. Joy: enjoyment, happiness, relief, bliss, delight, pride, thrill, and ecstasy. Interest: acceptance, friendliness, trust, kindness, affection, love, and devotion. Surprise: shock, astonishment, amazement, astound, and wonder. Disgust: contempt, disdain, scorn, aversion, distaste, and revulsion. Shame: guilt, embarrassment, chagrin, remorse, regret, and contrition. All other emotions are made up by combining these basic 8 emotions. Sometimes we have secondary emotions, an emotional reaction to an emotion. We learn these. Some examples of these are: o Feeling shame when you get angry. o Feeling angry when you have a shame response (e.g., hurt feelings). o Feeling fear when you get angry (maybe you’ve been punished for anger). There are many more. These are NOT wired into our bodies and brains, but are learned from our families, our culture, and others. When you have a secondary emotion, the key is to figure out what the primary emotion, the feeling at the root of your reaction is, so that you can take an action that is most helpful. .
    [Show full text]
  • MDMA and Sexual Behavior
    Note: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Substance Use & Misuse following peer review. The definitive publisher-authenticated version [McElrath K (2005) MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk, Substance Use & Misuse, 40:9, 1461-1477] is available online at http://www.informaworld.com/smpp/title~db=all~content=g714012467 MDMA and Sexual Behavior: Ecstasy Users’ Perceptions About Sexuality and Sexual Risk KAREN MCELRATH School of Sociology and Social Policy, Belfast, Ireland Published in Substance Use & Misuse,(2005) 40:9,1461—1477 This study examines the relationship between MDMA (Ecstasy), sexual behavior, and sexual risk taking. The sample consisted of 98 current and former users of MDMA. Several strategies were utilized to recruit respondents and data were collected through in-depth interviews during 1997 and 1998. The majority of respondents had used MDMA during the 6-month period prior to the interview and a large percentage had consumed the drug on 100 occasions or more. Most respondents reported feelings of emotional closeness while consuming MDMA but without the desire for penetrative sex. Others, however, reported that MDMA increased sexual arousal and some respondents (in particular gay and bisexual females) had used MDMA specifically for sexual enhancement. Sexual risk taking (e.g., having multiple partners, engaging in sex without a condom) was prevalent among respondents who did engage in sexual activity during MDMA episodes. Explanations for the findings are offered and implications for prevention/intervention are discussed. Keywords MDMA; ecstasy; sexual behavior Introduction Although a patent for 3,4-methylenedioxymethamphetamine (MDMA) was issued in 1914 (Shulgin, 1986), “recreational”a use of the drug did not surface until the 1970s and 1980s, and for the most part was restricted to selected regions in the U.S.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • 4-Methylethcathinone (4-MEC)
    4‐Methylethcathinone (4‐MEC) Critical Review Report Agenda item 4.15 (R/S)‐ 2‐(Ethylamino)‐1‐(4‐methylphenyl) propan‐1‐one (4‐methyl‐N‐ethylcathinone, 4‐MEC) Expert Committee on Drug Dependence Thirty‐sixth Meeting Geneva, 16‐20 June 2014 36th ECDD (2014) Agenda item 4.15 4‐Methylethcathinone (4‐MEC) Page 2 of 20 36th ECDD (2014) Agenda item 4.15 4‐Methylethcathinone (4‐MEC) Acknowledgements This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Policy Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this critical review report: Dr Simon Brandt, United Kingdom (literature review and drafting), Dr Caroline Bodenschatz, Switzerland (editing) and Mr David Beran, Switzerland (questionnaire report drafting). Page 3 of 20 36th ECDD (2014) Agenda item 4.15 4‐Methylethcathinone (4‐MEC) Page 4 of 20 36th ECDD (2014) Agenda item 4.15 4‐Methylethcathinone (4‐MEC) Contents Summary.................................................................................................................................................................... 7 1. Substance identification ............................................................................................................................... 8 A. International Nonproprietary Name (INN) ......................................................................................... 8 B. Chemical Abstract Service (CAS) Registry Number ..........................................................................
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • Phencyclidine (PCP) Abuse: an Appraisal
    PHENCYCLIDINE Latest Revision: May 16, 2005 1. SYNONYMS CFR: Phencyclidine CAS #: Base: 77-10-1 Hydrochloride: 956-90-1 Other Names: 1-(1-Phenylcyclohexyl) piperidine PCP Angel dust CI-395 Sernylan Sernyl 2. CHEMICAL AND PHYSICAL DATA 2.1. CHEMICAL DATA Form Chemical Formula Molecular Weight Melting Point (°C) Base C17H25N 243.4 46-46.5 Hydrochloride C17H26NCl 279.9 233-235 2.2. SOLUBILITY Form A C E H M W Base FS FS FS FS S VSS Hydrochloride SS FS I I FS FS A = acetone, C = chloroform, E = ether, H = hexane, M = methanol and W = water, VS = very soluble, FS = freely soluble, S = soluble, PS = sparingly soluble, SS = slightly soluble, VSS = very slightly soluble and I = insoluble 3. SCREENING TECHNIQUES 3.1. COLOR TESTS REAGENT COLOR PRODUCED p-Dimethylaminobenzaldehyde Red 3.2. CRYSTAL TESTS REAGENT CRYSTALS FORMED Potassium permanganate Bow-tie shaped 3.3. THIN-LAYER CHROMATOGRAPHY Visualization Acidified iodoplatinate spray Dragendorff spray COMPOUND RELATIVE R1 System System System TLC17 TLC11 TLC16 piperidine 0.4 0.2 0.1 PCP 1.0 1.0 1.0 piperidinocyclohexylcarbonitrile (PCC) 4.5 1.7 1.7 Both iodoplatinate and Dragendorff sprays will detect the three components. Iodine vapor produces a white spot outlined in brown for PCC, where as PCP and piperidine both give brown spots. 3.4. GAS CHROMATOGRAPHY Method PCP-GCS1 Instrument: Gas chromatograph operated in split mode with FID Column: 5% phenyl/95% methyl silicone 12 m x 0.2 mm x 0.33 µm film thickness Carrier gas: Helium at 1.0 mL/min Temperatures: Injector: 270°C Detector: 280°C Oven program: 1) 175°C initial temperature for 1.0 min 2) Ramp to 275°C at 15°C/min 3) Hold final temperature for 3.0 min Injection Parameters: Split Ratio = 60:1, 1 µL injected Samples are to be dissolved or diluted in chloroform and filtered.
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MEMANTINE and DONEPEZIL ---------------------CONTRAINDICATIONS -------------------- HYDROCHLORIDES EXTENDED-RELEASE Memantine and donepezil hydrochlorides extended-release CAPSULES safely and effectively. See full prescribing capsules are contraindicated in patients with known information for MEMANTINE and DONEPEZIL hypersensitivity to memantine hydrochloride, donepezil HYDROCHLORIDES EXTENDED-RELEASE hydrochloride, piperidine derivatives, or to any excipients CAPSULES. used in the formulation. (4) MEMANTINE and DONEPEZIL HYDROCHLORIDES ------------------WARNINGS AND PRECAUTIONS ---------- extended-release capsules, for oral use • Memantine and donepezil hydrochlorides extended- Initial U.S. Approval: 2014 release is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. (5.1) ------------------RECENT MAJOR CHANGES ----------------- • Memantine and donepezil hydrochlorides extended- Indications and Usage (1) 07/2016 release may have vagotonic effects on the sinoatrial and Dosage and Administration (2.1, 2.3) 07/2016 atrioventricular nodes manifesting as bradycardia or heart block. (5.2) ------------------INDICATIONS AND USAGE------------------ • Monitor patients for symptoms of active or occult Memantine and donepezil hydrochlorides extended-release gastrointestinal bleeding, especially those at increased capsules are a combination of memantine hydrochloride, an risk for developing ulcers. (5.3) NMDA receptor
    [Show full text]
  • WHO Expert Committee on Drug Dependence Thirty-Eighth Report
    WHO Expert Committee on Drug Dependence Thirty-eighth report This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization iii Contents WHO Expert Committee on Drug Dependence vi Abbreviations ix Introduction 1 1. Briefings from International Organizations on their work on the public health element of the world drug problem 4 1.1 Update from the International Narcotics Control Board 4 1.2 Update from the United Nations Office on Drugs and Crime 5 1.3 Update from the Department of Essential Medicines and Health Products, WHO 7 1.4 Update from the Department of Mental Health and Substance Abuse, WHO 9 1.5 Update from the Department of HIV/AIDS, WHO 9 2. Principles for prioritizing and assessing substances as part of ECDD work 11 3. Update from the 1st Informal Working Group of the ECDD 12 4. Follow-up on recommendations made by the ECDD at its thirty-seventh meeting 13 5. Critical review of psychoactive substances 14 5.1 U- 47700 15 5.2 Butyrfentanyl (Butyrylfentanyl) 17 5.3 4-Methylethcathinone (4-MEC) 18 5.4 3-Methylmethcathinone (3-methyl-N-methylcathinone; 3-MMC) 21 iv 5.5 Ethylone (3,4-metheylenedioxy-N-ethylcathinone; bk-MDEA; MEDEC) 23 5.6 Pentedrone (α-Methylaminovalerophenone) 24 5.7 Ethylphenidate (EPH) 26 5.8 Methiopropamine (MPA) 28 5.9 MDMB-CHMICA 30 5.10 5F-APINACA (5F-AKB-48) 32 5.11 JWH-073 34 5.12 XLR-11 36 6. Updates 37 6.1 Cannabis and cannabis resin 37 7.
    [Show full text]